GlassScriptPhysician profile
Steve M Dorman
NPI 1043519333
$207,521.08
in general payments reported to CMS, 2019-2025
25 companies · $119K in 2025
The $119K reported for 2025 was more than what 98% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $31.88 · 2021: $280 · 2022: $4,186 · 2023: $12K · 2024: $71K · 2025: $119K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $131K · Consulting Fee: $51K · Travel and Lodging: $12K · Food and Beverage: $8,094 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $131,090.00 |
| Consulting Fee | $51,061.21 |
| Travel and Lodging | $12,314.89 |
| Food and Beverage | $8,094.20 |
| Education | $118.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $94,702.33 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $38,419.43 | 2021-2025 | Takhzyro, Hyqvia, Cuvitru |
| Novartis Pharmaceuticals Corporation | $24,705.62 | 2019-2025 | |
| Ionis Pharmaceuticals, INC. | $24,266.62 | 2025 | Dawnzera |
| Biocryst US Sales Co., LLC | $9,307.13 | 2021-2024 | Orladeyo |
| Genentech, INC. | $5,838.92 | 2022-2024 | Xolair |
| Genentech USA, INC. | $4,965.31 | 2019-2024 | Xolair |
| Genzyme Corporation | $2,031.42 | 2019-2025 | |
| Cycle Pharmaceuticals INC | $1,120.00 | 2023 | |
| Biocryst Pharmaceuticals, INC. | $824.78 | 2024 | |
| Glaxosmithkline, LLC. | $192.49 | 2019-2024 | Nucala |
| Grifols USA, LLC | $176.07 | 2023-2025 | Xembify |
| Csl Behring | $169.95 | 2019-2025 | Hizentra, Andembry |
| Pharming Healthcare, INC. | $136.85 | 2019-2025 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $128.28 | 2019-2024 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $125.00 | 2025 | |
| Edwards Lifesciences Corporation | $96.36 | 2021 | |
| Pfizer INC. | $89.29 | 2019-2024 | |
| Amgen INC. | $67.29 | 2024-2025 | Tezspire |
| Kaleo, INC. | $40.02 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $35.15 | 2022-2024 | Ryaltris |
| Incyte Corporation | $25.05 | 2021 | |
| Merck Sharp & Dohme LLC | $21.99 | 2023 | |
| Optinose US, INC. | $21.96 | 2024 | |
| Aimmune Therapeutics, INC. | $13.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Dorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.